SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 6th, 2009 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 5, 2009, between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
12,244,898 Shares and Warrants to purchase 7,346,939 Shares PLURISTEM THERAPEUTICS INC. AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • January 20th, 2017 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 3rd, 2021 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 2, 2021, between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
At Market Issuance Sales AgreementPluristem Therapeutics Inc • July 7th, 2017 • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), MLV & Co. LLC (“MLV”) and Oppenheimer & Co. Inc. (“Oppenheimer”; each of FBR, MLV and Oppenheimer individually an “Agent” and collectively, the “Agents”), as follows:
COMMON STOCK PURCHASE WARRANT PLURI INC.Common Stock Purchase • December 19th, 2022 • Pluri Inc. • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time following the Initial Exercise Date (as hereinafter defined) and on or prior to the close of business on the three (3) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pluri Inc., a Nevada corporation (the “Company”), up to [___________] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIALPluristem Therapeutics Inc • May 6th, 2009 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and Pluristem Therapeutics Inc. (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock. The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Compan
SUBSCRIPTION AGREEMENTSubscription Agreement • May 24th, 2007 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances) • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of May ____, 2007, by and among Pluristem Life Systems, Inc., a Nevada corporation (the “Company”), and the subscribers identified on the signature page hereto (each a “Subscriber” and collectively “Subscribers”).
Pluristem Therapeutics Inc. and American Stock Transfer & Trust Company, LLC, as Warrant AgentWarrant Agent Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
WARRANT AGENT AGREEMENT, dated as of April 4, 2019 (“Agreement”), between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Warrant Agent”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • July 16th, 2020 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
PLURISTEM THERAPEUTICS INC. 11,000,000 Shares and Warrants to purchase 4,400,000 Shares UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2011 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Pluri Inc. COMMON SHARES SALES AGREEMENTSales Agreement • February 13th, 2024 • Pluri Inc. • Biological products, (no disgnostic substances) • New York
Pluri Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows:
PLACEMENT AGENCY AGREEMENT October 6, 2009Placement Agency Agreement • October 6th, 2009 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) 2,702,822 shares (the “Shares”) of its common stock, $0.00001 par value per share (the “Common Stock”), and (ii) warrants to purchase 1,081,129 shares of Common Stock (the “Warrants”, and together with the Shares, the “Securities”), to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-151761). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the Warrant Shares. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Roth Capital Partners, LLC (“Roth Capital”) in connection with such issuance and sale of the Securities.
At Market Issuance Sales AgreementPluristem Therapeutics Inc • December 26th, 2012 • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 6th, 2009 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 6, 2009, between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 3rd, 2021 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (“A.G.P.”)(A.G.P. is also referred to as, the “Placement Agent”), and Pluristem Therapeutics Inc., a company organized under the laws of the State of Nevada (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares of common stock, par value, $0.00001 per share (the “Shares”). The Shares actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-239890) with respect to the Placement Agent Securities. The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities pu
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT...Pluristem Therapeutics Inc • October 12th, 2010 • Biological products, (no disgnostic substances)
WARRANT AGREEMENTWarrant Agreement • November 6th, 2012 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
WARRANT AGREEMENT made as of September 19, 2012 (“Issuance Date”), between Pluristem Therapeutics Inc., a Nevada corporation (“Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability company (“Warrant Agent”).
Mr. Zami Aberman, Chairman of Board of Directors & Chief Executive OfficerPluristem Therapeutics Inc • June 25th, 2015 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Pluristem Therapeutics Inc. (the “Company”), that Maxim shall serve as the lead placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) registered shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) to purchase shares of Common Stock (the shares of Common Stock underlying the Warrants, “Warrant Shares” and, together with the Shares and the Warrants, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or com
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 27th, 2004 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances) • New York
THIS REGISTRATION RIGHTS AGREEMENT, dated as of January ___ 2004 (this "Agreement"), is made by and between PLURISTEM LIFE SYSTEMS, INC., a Nevada corporation with headquarters located at MATAM Advanced Technology Park, Building No. 20, Haifa, Israel (the "Company"), and each entity named on a signature page hereto (each, an "Initial Investor") (each agreement with an Initial Investor being deemed a separate and independent agreement between the Company and such Initial Investor, except that each Initial Investor acknowledges and consents to the rights granted to each other Initial Investor under such agreement).
STOCK OPTION AGREEMENTStock Option Agreement • December 29th, 2003 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances)
PLURISTEM LIFE SYSTEMS, INC., a company incorporated pursuant to the laws of the State of Nevada, having its head office located at MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905 (the "Company")
FORM OF WARRANTPluristem Life Systems Inc • April 5th, 2006 • Biological products, (no disgnostic substances)
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
PLURISTEM THERAPEUTICS INC. 27,142,858 Shares and Warrants to purchase 27,142,858 Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
PLURISTEM THERAPEUTICS INC., a Nevada corporation (the “Company”), proposes to issue and sell to Ladenburg Thalmann & Co. Inc. (the “Representative”) and the other underwriters listed on Schedule I hereto (collectively, with the Representative, the “Underwriters”), pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”) in a public offering (the “Offering”), an aggregate of 27,142,858 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”), and warrants (each whole warrant, a “Warrant”) to purchase up to an aggregate of 27,142,858 shares of Common Stock. The Shares to be sold by the Company are called the “Firm Shares.” The Firm Shares and the Warrants will be sold as units (the “Units”), with each Unit consisting of one Share and a Warrant to purchase one Share. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,428,571 Shares as provided in Secti
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 5th, 2006 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances) • New York
THIS SECURITIES PURCHASE AGREEMENT, dated as of April 3, 2006 (this “Agreement”), is entered into by and between PLURISTEM LIFE SYSTEMS, INC., a Nevada corporation with headquarters located at MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905 (the “Company”), and each individual or entity named on an executed counterpart of the signature page hereto (each such signatory is referred to as a “Buyer”) (each agreement with a Buyer being deemed a separate and independent agreement between the Company and such Buyer, except that each Buyer acknowledges and consents to the rights granted to each other Buyer [each, an “Other Buyer”] under such agreement and the Transaction Agreements, as defined below, referred to therein).
ContractSubscription Agreement • February 27th, 2004 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances) • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
WARRANT TO PURCHASE COMMON STOCK OF PLURISTEM LIFE SYSTEMS, INC. (the “Company”) VOID AFTER 17:00 p.m. N.Y. Time on the last day of the Term (as set forth in Section 1 below)Pluristem Life Systems Inc • April 27th, 2005 • Biological products, (no disgnostic substances)
This is to certify that, for value received, YOKIM ASSET MANAGEMENT CORP., or its registered assigns (the “Holder”) is entitled to purchase, subject to the provisions of this Warrant, from the Company an aggregate of 50,000 fully paid and non-assessable shares of the Common Stock, as adjusted from time to time as provided below (“Common Stock” and such shares, the “Warrant Shares”) of the Company, as constituted on the date hereof (the “Warrant Issue Date”), upon surrender of this Warrant and the Notice of Exercise annexed hereto, duly completed and executed on behalf of the Holder, at the principal office of the Company referred to below, and simultaneous payment therefor in lawful money of the United States, at the Exercise Price as set forth in Section 2 below. The number, character and Exercise Price of such shares of Common Stock are subject to adjustment as provided below.
Amended and Restated Employment Agreement Duly made and executed on the date set forth in Appendix 1 By and Between Pluristem Ltd. Company number 513371666 (hereinafter the “Company”) and Yaacov (Yaky) Yanay I.D. 28621605 (hereinafter the “Employee”)...Employment Agreement • September 10th, 2020 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
WHEREAS, the Employee has been employed by the Company since October 15, 2006 and the Employee and the Company seek to enter into this Employment Agreement (the “Agreement”) to set forth the terms of the Employee’s employment as the Company’s Chief Financial Officer; and
RESTRICTED STOCK UNITS AGREEMENTRestricted Stock Units Agreement • February 12th, 2024 • Pluri Inc. • Biological products, (no disgnostic substances)
WHEREAS on March 29, 2016, the Company duly adopted and the Compensation Committee approved the 2016 Equity Compensation Plan and on May 31, 2016, the Company’s stockholders approved the adoption of the 2016 Equity Compensation Plan, a copy of which has been made available to the Participant, forming an integral part hereof (the “Plan”); and -
Pluristem Therapeutics Inc. STOCK OPTION AGREEMENT Made as of the _______________Stock Option Agreement • September 23rd, 2009 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
WHEREAS On November 10, 2005, the Company duly adopted and the Board approved the 2005 Stock Option Plan. On January 21, 2009, the Company’s stockholders approved the adoption of the Amended and Restated 2005 Stock Option Plan, a copy of which has been made available to the Optionee, forming an integral part hereof (the “ISOP”); and –
PLURISTEM LIFE SYSTEMS INC. INVESTORS’ RIGHTS GREEMENTInvestors’ Rights Agreement • April 27th, 2005 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances)
THIS INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 25th day of October, 2004, by and among Pluristem Life Systems Inc., a Nevada corporation (the “Company”) and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” with respect to the shares of Common Stock held by it and collectively the ”Investors”).
PLURISTEM LIFE SYSTEMS, INC. COMMON STOCK PURCHASE AGREEMENTPurchase Agreement • April 27th, 2005 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances)
This Common Stock Purchase Agreement (this “Agreement”), is made as of March 3, 2005, by and between PLURISTEM LIFE SYSTEMS, INC., a Nevada corporation whose business address is at Matam Centre, Building 20, Haifa, 31905 Israel (the “Company”), and ERETZ HACARMEL LTD. (the “Investor”) whose address is at ________________________, Israel.
ESCROW AGREEMENTEscrow Agreement • April 27th, 2005 • Pluristem Life Systems Inc • Biological products, (no disgnostic substances)
PLURISTEM LIFE SYSTEMS, INC., a Nevada company, having an office at Matam Centre, Building 20, Haifa, 31905, Israel (herein called “Pluristem”)
STOCK PURCHASE AGREEMENT (Affiliate)Stock Purchase Agreement • July 22nd, 2003 • Pluristem Life Systems Inc • Services-prepackaged software
The Seller is the owner of 3,850,000 shares of common stock, par value $0.001 per share (the "Common Stock"), of A.I. Software, Inc. , a Nevada corporation (the "Company"); and
Consulting AgreementConsulting Agreement • February 13th, 2023 • Pluri Inc. • Biological products, (no disgnostic substances)
This Consulting Agreement (the “Agreement”) is entered into as of January 1st 2023 (the “Effective Date”) by and between Pluri Biotech Ltd., with its principal place of business at MATAM Park, Building 5, Haifa 31905 Israel (“Company”), and Mr. Zalman (Zami) Aberman, Israeli ID# 26014043 from Tel Mond, Israel (“Consultant”).
SUBSCRIPTION AGREEMENTSubscription Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
This Subscription Agreement (this “Subscription”) is dated as of April 4, 2019, by and between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and the investor identified on the signature page hereto (including its successors and assigns, the “Investor”).
Pluri Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of ___________________Restricted Stock Units Agreement • February 12th, 2024 • Pluri Inc. • Biological products, (no disgnostic substances)
WHEREAS on March 29, 2016, the Company duly adopted and the Compensation Committee approved the 2016 Equity Compensation Plan and on May 31, 2016, the Company’s stockholders approved the adoption of the 2016 Equity Compensation Plan, a copy of which has been made available to the Participant, forming an integral part hereof (the “Plan”); and -
